BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18174309)

  • 1. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay.
    Wong AK; Chan RC; Nichols WS; Bose S
    J Clin Microbiol; 2008 Mar; 46(3):869-75. PubMed ID: 18174309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance.
    Halfon P; Trepo E; Antoniotti G; Bernot C; Cart-Lamy P; Khiri H; Thibaud D; Marron J; Martineau A; Pénaranda G; Benmoura D; Blanc B;
    J Clin Microbiol; 2007 Feb; 45(2):313-6. PubMed ID: 17122007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples.
    Sandri MT; Lentati P; Benini E; Dell'Orto P; Zorzino L; Carozzi FM; Maisonneuve P; Passerini R; Salvatici M; Casadio C; Boveri S; Sideri M
    J Clin Microbiol; 2006 Jun; 44(6):2141-6. PubMed ID: 16757611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.
    Recio FO; Sahai Srivastava BI; Wong C; Hempling RE; Eltabbakh GH; Piver MS
    Eur J Gynaecol Oncol; 1998; 19(3):203-8. PubMed ID: 9641214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia.
    Arbyn M; Buntinx F; Van Ranst M; Paraskevaidis E; Martin-Hirsch P; Dillner J
    J Natl Cancer Inst; 2004 Feb; 96(4):280-93. PubMed ID: 14970277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pap cytopathology and the presence of high-risk human papillomavirus in SurePath liquid preservative and Digene cervical sampler specimens.
    Kapala J; Jang D; Patel J; Biers K; Smieja M; Chernesky M
    J Virol Methods; 2007 Jun; 142(1-2):223-5. PubMed ID: 17320978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of human papillomavirus prevalence in women in Eskişehir, Turkey by Pap smear, hybrid capture 2 test and consensus real-time polymerase chain reaction and typing with pyrosequencing method].
    Aslan FG; Us T; Kaşifoğlu N; Özalp SS; Akgün Y; Öge T
    Mikrobiyol Bul; 2016 Jan; 50(1):73-85. PubMed ID: 27058331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing atypical squamous cells of undetermined significance in Papanicolaou smears.
    Morin C; Bairati I; Bouchard C; Fortier M; Roy M; Moore L; Meisels A
    J Reprod Med; 2001 Sep; 46(9):799-805. PubMed ID: 11584480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness.
    Kaufman RH; Adam E; Icenogle J; Reeves WC
    Am J Obstet Gynecol; 1997 Oct; 177(4):930-6. PubMed ID: 9369847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL.
    Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Woodward L
    J Fam Pract; 1998 Feb; 46(2):136-41. PubMed ID: 9487319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions.
    Clavel C; Masure M; Levert M; Putaud I; Mangeonjean C; Lorenzato M; Nazeyrollas P; Gabriel R; Quereux C; Birembaut P
    Diagn Mol Pathol; 2000 Sep; 9(3):145-50. PubMed ID: 10976721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
    De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
    J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
    Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
    Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.
    Basu P; Banerjee D; Mittal S; Dutta S; Ghosh I; Chowdhury N; Abraham P; Chandna P; Ratnam S
    J Med Virol; 2016 Jul; 88(7):1271-8. PubMed ID: 26693677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
    Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
    Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.